Home | Contact Us | About Us | Site Map
Miracle II Products | Suggested Uses | M II Testimonials | Order Miracle II | Health News | Links | Business Opportunity | Refer-A-Friend | Vitalzym | Garden of Life | GIA Wellness | Harmony Formulas | U-Fucoidan | Zymessence


Fucoidan Research

U-Fn (Fucoidan) Cancer Research

Bottle of U-Fn cancer treatment
FREE SHIPPING
US ORDERS ONLY

Qty

PMID: 8702239, UI: 96273150
Anticancer Res 1996 May-Jun;16(3A):1213-8
Antitumor and antiproliferative effects of a fucan extracted from ascophyllum nodosum against a non-small-cell bronchopulmonary carcinoma line.

Riou D, Colliec-Jouault S, Pinczon du Sel D, Bosch S, Siavoshian S, Le Bert V, Tomasoni C, Sinquin C, Durand P, Roussakis C. ISOMer (Institut des Substances et Organismes de la Mer), SMAB, Laboratoire de Pharmacologie Marine, Faculte de Pharmacie, Nantes, France.

Fucans, sulfated polysaccharides extracted from brown seaweeds, have been shown to be endowed with inhibitory effects cell growth in various experimental models. We studied both the antiproliferative and antitumor properties of a fucoidan extract (HF) obtained from the brown seaweed Ascophyllum nodosum on a cell line derived from a non-small-cell human bronchopulmonary carcinoma (NSCLC-N6); this type of carcinoma is particularly chemoresistant. HF exerts in vitro a reversible antiproliferative activity with a block observed in the G1 phase the cell cycle. Studies performed with the NSCLC-bearing nude mice show antitumor activity at subtoxic doses. These preliminary results indicate that HF exhibits inhibitory effect both in vitro and in vivo and is very potent antitumor agent in cancer therapy.

PMID: 6513098, UI: 85083654
Jpn J Exp Med 1984 Aug;54(4):143-51
Antitumor effect of seaweeds. IV. Enhancement of antitumor activity by sulfation of a crude fucoidan fraction from Sargassum kjellmanianum.

Yamamoto I, Takahashi M, Suzuki T, Seino H, Mori H

We have reported an antitumor aqueous extract from a brown marine alga Sargassum kjellmanianum ("Hahakimoku" in Japanese). Although the extract was effective in the in vivo growth inhibition of the implanted Sarcoma-180 cells, it was not effective against L-1210-bearing mice. In the present study, we attempted to obtain a polysaccharide fraction with antitumor activity against L-1210 leukemia from this alga, on the assumption that the main active substance may be sulfated polysaccharide, especially fucoidan which is mainly composed of L-fucose and ester sulfate. Two kinds of polysaccharide fractions (SKCF and SKCF-F), which contained L-fucose and ester sulfate in the amount of 12.6% and 15.4%, 23.5% and 17.2% respectively, were first prepared starting with extraction with cold-hydrochloric acid, and their antitumor activity was examined. It was found however that they are not effective. Sulfation of SKCF was then carried out. The resulting sulfate (Sulfated SKCF) was observed to contain nearly 50% more ester sulfate than in SKCF and to be effective against L-1210 leukemia showing an ILS value of 26%. Mechanisms of antitumor action of this sulfate were also discussed from the viewpoints of negativity of ester sulfate and of activation of host-mediated immune response as known in antitumor polysaccharide preparations from other sources.

PMID: 9521847, UI: 98189141
Cell Res 1998 Mar 15;239(2):301-10
Sulfated glycosaminoglycans enhance tumor cell invasion in vitro by stimulating plasminogen activation.

Brunner G, Reimbold K, Meissauer A, Schirrmacher V, Erkell LJ Division of Cellular Immunology, German Cancer Research Centre, Heidelberg, Germany. Georg.Brunner@man.ac.uk

Metastasizing tumor cells invade host tissues by degrading extracellular matrix constituents. We report here that the highly sulfated glycosaminoglycans, heparin and heparan sulfate, as well as the sulfated polysaccharide, fucoidan, significantly enhanced tumor cell invasion in vitro into fibrin, the basement membrane extract, Matrigel, or through a basement membrane-like extracellular matrix.
The enhancement of tumor cell invasion was due to a stimulation of the proteolytic cascade of plasminogen activation since the effect required plasminogen activation and was abolished by inhibitors of urokinase-type plasminogen activator (uPA) or plasmin. Sulfated polysaccharides enhanced five reactions of tumor-cell initiated plasminogen activation in a dose-dependent manner. They amplified plasminogen activation in culture supernatants up to 70-fold by stimulating (i) pro-uPA activation by plasmin and (ii) plasminogen activation by uPA. (iii) In addition, sulfated polysaccharides partially protected plasmin from inactivation by alpha 2-antiplasmin. Sulfated polysaccharides also stimulated tumor-cell associated plasminogen activation, e.g., (iv) cell surface pro-uPA activation by plasmin and (v) plasminogen activation by cell surface uPA. These results suggest that sulfated glycosaminoglycans liberated by tumor-cell mediated extracellular matrix degradation in vivo might amplify pericellular plasminogen activation and locally enhance tumor cell invasion in a positive feedback manner.

PMID: 8702239, UI: 96273150
Anticancer Res 1996 May-Jun;16(3A):1213-8
Antitumor and antiproliferative effects of a fucan extracted from ascophyllum nodosum against a non-small-cell bronchopulmonary carcinoma line.Riou D, Colliec-Jouault S, Pinczon du Sel

D, Bosch S, Siavoshian S, Le Bert V, Tomasoni C, Sinquin C, Durand P, Roussakis C
ISOMer (Institut des Substances et Organismes de la Mer), SMAB, Laboratoire de Pharmacologie Marine, Faculte de Pharmacie, Nantes, France.

Fucans, sulfated polysaccharides extracted from brown seaweeds, have been shown to be endowed with inhibitory effects cell growth in various experimental models. We studied both the antiproliferative and antitumor properties of a fucoidan extract (HF) obtained from the brown seaweed Ascophyllum nodosum on a cell line derived from a non-small-cell human bronchopulmonary carcinoma (NSCLC-N6), this type of carcinoma is particularly chemo-resistant. HF exerts in vitro a reversible antiproliferative activity with a block observed in the G1 phase the cell cycle. Studies performed with the NSCLC-bearing nude mice show antitumor activity at subtoxic doses. These preliminary results indicate that HF exhibits inhibitory effect both in vitro and in vivo and is very potent antitumor agent in cancer therapy.

PMID: 7532138, UI: 95163724
Eur J Haematol 1995 Jan;54(1):27-33
Changes in adhesion molecule expression and function in B-cell chronic lymphocytic leukaemia after in vitro interferon-alpha stimulation.

Csanaky G, Vass JA, Ocsovszki I, Milosevits J, Szomor A, Schmelczer M Department of Pathology, University Medical School of Pecs, Hungary.

Peripheral blood mononuclear cells (PBMCs) from 10 B-CLL patients were investigated after 24 hours of in vitro interferon-alpha (IFN-alpha) stimulation. The constitutional expression of the L-selectins (LECAM-1), LFA-1/CD11a, VLA alpha-4/CDw49d and ICAM-1/CD54 adhesion molecules was detected, and changes in their density after IFN-alpha stimulation were compared to results obtained by the high endothelial venule (HEV)-binding assay and a carbohydrate (phosphonomannan core polysaccharide: PPME and fucoidin) immobilization test. The LECAM-1 and ICAM-1 molecules were expressed on the great majority of CLL cells, while the LFA-1 and VLA-4 alpha-chains were expressed by only a small number of cells. Statistically significant changes (p < 0.001) were observed in LECAM-1 antigen density (changes in mean cell fluorescence), as well as in functional tests (HEV-, PPME- and fucoidin-binding; p < 0.01) after in vitro IFN-alpha stimulation. Based on a prior study (Jewell et al., Leukemia 1992: 6: 400-404) and on the present findings, not only an increased expression but also an enhanced function of the L-selectins seem to be well substantiated after IFN-alpha stimulation, which may explain the therapeutic effect of IFN-alpha in reducing the accumulation of leukaemic B cells in the blood. The remarkably high expression of ICAM-1 in this series necessitates further studies to clarify the exact expression rate and role of this molecule.

U-FN

Last updated:

Copyright 2017, TMN Health, All rights reserved.